For 1L treatment, patients with KRAS WT cancer received, in order of frequency, chemotherapy alone (69.7%), combination CIT and chemotherapy (19.5%), or CIT alone (10.8%); similarly, the majority of patients with KRAS G12C–positive cancer received chemotherapy alone (61.9%), combination CIT and chemotherapy (22.2%), and CIT alone (15.9%) (Table 1). This evidence concerns the gene KRAS and cancer.